Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
Mar 2023Hemophilia A and B
Nov 2022Non-Alcoholic Steatohepatitis
Apr 2023Obesity Management
Sep 2022Menopause: Vasomotor Symptoms
Dec 2022Sickle Cell Disease
Jun 2023Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
Featured News & Insights.
Learn about our latest work.
ICER Identifies Most Significant 2021 US Drug-Price Hikes Unsupported by New Clinical Evidence
Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.
12/06/2022Leigh Purvis Elected New Governance Board Chair of ICER
National leader for AARP on policies to improve the affordability of prescription drugs for seniors brings decades of experience to the role.
12/05/2022ICER Publishes Evidence Report on Fezolinetant for Vasomotor Symptoms Associated with Menopause
Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for patients over the long term; however, using point estimates from short-term clinical trials, analyses suggest this drug would achieve common thresholds for cost-effectiveness if priced between $2,000 – $2,500 per year for women who cannot or choose not […]
12/01/2022The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Latest
Developments.
We recently celebrated our 15th anniversary! Learn more.
Dr. Melanie Whittington, ICER’s Director of Health Economics, received the Bernie O’Brien New Investigator Award, which recognizes those who have shown evidence of exceptional promise based on their emerging body of technical and scholarly work in the field of health economics. Learn more.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Current
Policy Papers.
Easy access to our latest policy papers
Barriers to Fair Access
First-ever scorecard of several key appropriate access criteria reveals variation across largest payers but high concordance for clinical eligibility criteria, step therapy, and provider restrictions; lower concordance found for formulary tiering criteria.
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.
Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.